Boca Medical Products recalls Ultilet Insulin Syringe
Boca Medical Products and the FDA have notified consumers andhealthcare professionals of a recall of Ultilet Insulin Syringe 30g1/2cc (Lot #-5GEXI; NDC #-08326-3002-50) because ofpossible bacterial presence of Bacillus cereus and Staphylococcusintermedius. This presents a risk of local infection due to softtissue injection with a contaminated syringe as well as a risk ofintroduction of contaminating organisms into a previously sterilevial.
Boca Medical Products and the FDA have notified consumers and healthcare professionals of a recall of Ultilet Insulin Syringe 30g 1/2cc (Lot #-5GEXI; NDC #-08326-3002-50) because of possible bacterial presence of Bacillus cereus and Staphylococcus intermedius. This presents a risk of local infection due to soft tissue injection with a contaminated syringe as well as a risk of introduction of contaminating organisms into a previously sterile vial. The introduced contamination may degrade the insulin, which could lead to problems for patients maintaining their insulin levels. This product has been distributed to the following states: Alabama, Arkansas, Colorado, Florida, Massachusetts, Mississippi, New York, North Carolina, South Carolina, and Texas. For any questions, consumers should call 1-(800) 354-8460. The safety summary can be found at http://www.fda.gov/medwatch/safety/2006/safety06.htm#boca.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
To go to the Drug Topics homepage, click here http://www.drugtopics.com.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.
